222037-06-1

Basic information

• Product Name: Benzenesulfonamide, 4-amino-N-(3-hydroxy-2,2-dimethylpropyl)-
• CAS NO: 222037-06-1
• Molecular Formula: C11H18N2O3S
• Molecular Weight: 258.342
• Mol File: 222037-06-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, 4-amino-N-(3-hydroxy-2,2-dimethylpropyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, 4-amino-N-(3-hydroxy-2,2-dimethylpropyl)-(222037-06-1)
• EPA Substance Registry System: Benzenesulfonamide, 4-amino-N-(3-hydroxy-2,2-dimethylpropyl)-(222037-06-1)

Safety Data

• Hazardous Substances Data: 222037-06-1(Hazardous Substances Data)

Upstream product

• 26734-09-8 3-amino-2,2-dimethylpropan-1-ol 
• 98-62-4 4-aminobenzenesulfonyl fluoride 

Downstream Products

• 363621-57-2 4-Amino-5-cyano-2-{4-[N-(3-hydroxy-2.2-dimethylpropyl)sulphamoyl]anilino}pyrimidine 
• 222035-75-8 N-(3-Hydroxy-2,2-dimethyl-propyl)-4-[(7-oxo-6,7-dihydro-1-thia-3,6-diaza-as-indacen-8-ylidenemethyl)-amino]-benzenesulfonamide 

Relevant articles and documents

4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases

Compounds of formula (I) wherein: R1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; p is 0-4; wherein the values of R1 may be the same or different; R2 is sulphamoyl or a group B—E—; wherein B is optionally substituted as defined within and is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C1-6alkyl, phenyl, a heterocyclic group, phenylC1-6alkyl or (heterocyclic group)C1-6alkyl; E is C(O)—, N(Ra)C(O)—, —C(O)N(Ra)—, —S(O)r—, —SO2N(Ra)— or —N(Ra)SO2—; wherein Ra is hydrogen or C1-6alkyl optionally substituted as defined within and r is 1-2; q is 0-2; wherein the values of R2 may be the same or different; and wherein p+q=1-5; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof are described. Processes for their manufacture and their use as inhibitors of cell cycle kinases, particularly CDK2, CDK4 and/or CDK6 are also described.